Report on Mitesco (MITI): Zacks Issues $0.53 Price Target, a 165% Potential Gain.
LIVE QUOTE
Original Report: Initiating Coverage...
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
Adding VYRE Network (CAPV) to the Watch List.
Look What We Found. Our First Internet Play in Ages, And It's a Doozy.
We would categorize this...
OMNIQ (OMQS) Graduates to NASDAQ. And Three Wall Street Research Reports Follow.
Wall Street Brokerage Price Target Estimates of $15 - $18 Per Share.
Without disrupting legacy sales - CEO Shai...
Report: Ehave Inc (EHVVF) Our Favorite Psychedelic Company
WE LOOKED FAR AND WIDE TO FIND OUR FAVORITE
What exactly is a favorite?
First...
Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.
Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022.
CITIUS NEWS ARCHIVE
Up 191%, HealthLynked (HLYK) Reporting Decent Numbers.
Up as much as 417% from where we added it to the Watch List, the Company continues to report increasing revenues while...
Bitcoin $30,000. Time to Bargain Hunt? Read This First.
The Bit Short: Inside Crypto’s Doomsday Machine
Scary article on Tether/Bitcoin posted on...
Initiating Coverage on Society Pass (SOPA).
Institutional Analyst: Society Pass (Nasdaq: SOPA) - Acquiring and Incubating Startups in the Heart of the Asian Silicon Valley
Draganfly (DFLYF) Holds ‘Pole Position’ in Race for Drone Supremacy After Chinese Barred from...
STREETWISE REPORTS - March 3, 2020
The company establishes a toehold with U.S....